Injectable vs. Oral Corticosteroids: Side Effect Profile
Injectable and oral corticosteroids share the same systemic adverse effects when absorbed, but injectable formulations carry additional unique local complications that oral preparations do not cause.
Shared Systemic Side Effects
Both routes of administration can produce identical systemic adverse effects once the corticosteroid enters circulation 1:
- HPA axis suppression (observed with both intralesional and systemic steroids, incidence estimates vary from 1.7% to 87%)
- Cushingoid features
- Growth deceleration (temporary, with "catch-up" growth after completion)
- Weight gain/increased appetite
- Hypertension
- Gastric irritation
- Irritability and insomnia
- Immune suppression with increased infection risk
- Cardiomyopathy
- Steroid myopathy
- Osteopenia and reduced bone mineral density 2, 3
- Ocular adverse effects (glaucoma, cataracts)
- Hyperglycemia 2, 3
Injectable-Specific Local Complications
Injectable corticosteroids produce distinct local adverse effects that cannot occur with oral administration 3, 4, 5:
Immediate Local Effects:
- Postinjection flare (pain at injection site)
- Facial flushing and sweating (specific to corticosteroid injection) 2
- Vasovagal reactions (2.5% incidence) 2
- Transient nerve block if local anesthetic included 2
Delayed Local Effects:
- Skin hypopigmentation and atrophy (particularly with less soluble preparations like triamcinolone) 6, 3, 4
- Fat atrophy at injection site
- Tendon rupture and tendinopathy risk 3, 4
- Accelerated cartilage damage and osteoarthritis progression (chondrotoxicity with particulate formulations) 4, 5
- Calcifications 4
- Osteonecrosis 2, 4
- Infection risk (rare but includes joint infection, epidural abscess) 2
Critical Formulation Differences:
Particulate corticosteroids (triamcinolone acetonide, methylprednisolone acetate) have:
- Low aqueous solubility
- Microcrystal formation
- Prolonged tissue residence
- Higher risk of local tissue damage 4
Soluble preparations (betamethasone, dexamethasone sodium phosphate) have:
- Rapid onset, shorter duration
- Reduced local depot-related complications
- Greater propensity for transient systemic effects 4
Evidence on Comparative Safety
Polymyalgia Rheumatica:
A 2015 EULAR/ACR guideline noted that intramuscular methylprednisolone failed to demonstrate reduction in GC-related adverse events except for weight gain compared to oral therapy 7. The panel acknowledged lack of convincing evidence showing significantly fewer side effects with i.m. versus oral preparations.
COPD Exacerbations:
One trial showed increased mild adverse effects with intravenous corticosteroids (70% vs. 20%; RR 3.50) including more hyperglycemia (11 vs. 4 patients) and worsening hypertension (3 vs. 0 patients) 8. However, the IV arm used higher doses, confounding interpretation.
Acute Asthma:
A 2018 Cochrane review found no statistical difference in adverse events between IM and oral corticosteroids (RR 0.83,95% CI 0.64-1.07), though an estimated 50 fewer patients per 1000 receiving IM reported adverse events 9.
Clinical Implications
The route of administration does not eliminate systemic side effects—both injectable and oral corticosteroids cause the same systemic complications once absorbed. The key distinction is that injectable formulations add a layer of local tissue risks including skin atrophy, tendon damage, and cartilage injury that are impossible with oral therapy 3, 4, 5.
Ultrasound guidance significantly reduces local complications by improving injection accuracy and optimizing drug deposition 4, 5.
For conditions requiring systemic corticosteroid therapy (asthma, COPD, polymyalgia rheumatica), oral preparations avoid injection-site complications while achieving equivalent systemic efficacy 10, 7, 8, 9. Injectable routes may be considered when adherence is a concern 11, 9, 12 or when targeting localized pathology (joints, bursae) 6, 2, 5.